Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Conditions
Interventions
Lenalidomide
Dexamethasone
+5 more
Locations
235
United States
Local Institution - 1628
Birmingham, Alabama, United States
Local Institution - 7619
Mobile, Alabama, United States
Local Institution - 7618
Mobile, Alabama, United States
Local Institution - 7617
Chandler, Arizona, United States
Local Institution - 1644
Tucson, Arizona, United States
Local Institution - 1618
Bakersfield, California, United States
Start Date
August 4, 2011
Primary Completion Date
October 1, 2019
Completion Date
September 3, 2021
Last Updated
September 30, 2022
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions